An Observational Study of Patients With Chronic Lymphocytic Leukemia Treated With Fixed Duration Therapy in a 1L Setting in Canada.

Authors

Carolyn Owen, Sydney George, Sandra Thibault, Mariet Mathew Stephen, Mackenzie A Hamilton, Simar Gill, Winson Y Cheung

Published in

Clinical lymphoma, myeloma & leukemia. Aug 06, 2026. Epub Aug 06, 2026.

Abstract

Targeted fixed duration (FD) therapies have emerged as new treatment options that have been shown to be highly effective for patients with chronic lymphocytic leukemia (CLL). To date, there is limited Canadian data on the uptake and outcomes of CLL treatment following the approval of FD therapy.
This study was conducted to evaluate the clinical and demographic characteristics, treatment outcomes, and healthcare resource utilization (HCRU) of CLL patients treated with FD treatments in the 1L setting between 01 January 2010 and 31 December 2023 in Alberta, Canada.
In total, 589 patients received therapy for CLL during this time period, and venetoclax plus obinutuzumab (VO) represented the most common therapy from 2021 to 2023. Additionally, patients receiving VO showed the highest survival rates at 12 months (95% confidence interval [CI]) at 97.6% (94.5, 100.0), followed by fludarabine, cyclophosphamide, and rituximab (FCR) at 96.6% (94.0, 99.3).
These results highlight the shift in the treatment landscape for CLL with the potential for improved patient outcomes.

PMID:
42692910
Bibliographic data and abstract were imported from PubMed on 04 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.